In the second half of 2024, the Ministry of SMEs and Startups' Export Voucher Program provided funding totaling 65 million won (approximately 45 million won from the government and 20 million won from the company) for overseas certification, promotion, and patent application expenses. This funding can be used for pre-promotion and export promotion of the Anyfusion Cylinder pump and ACPi Pro.

Overseas certification costs cover testing fees for Anyfusion Cylinder pump EC MDR and FDA 510K approvals. Promotion expenses will fund website updates: 1) adding the new Anyfusion ACPi Pro product, and 2) ACPi Pro compatibility and the upgraded MCSTD1, 2 for universal Cylinder pump use, along with information on its usefulness. 3) We aim to create a website on par with global major companies, focusing on papers demonstrating the clinical usefulness of the Cylinder pump in real-world references.

Patent expenses will cover domestic filing fees for the third patent for ACPi Pro and Cylinder Pump, as well as PCT application fees. This strengthens Anyfusion's intellectual property rights, contributing to stable export growth.

Anyfusion Cylinder Pump, recognized by the FDA as an innovative medical device (STeP), already addresses the shortcomings of global pharmaceutical infusion pump companies. Its world-leading clinical utility is immediately verifiable and validatable in real-world clinical use, proving superior to any major company's product. When used in combination with MCSTD1 and 2, it not only prevents contamination and infection but also reduces workload. By adopting the optimal usage paradigm tailored to Anyfusion in real-time, users immediately experience its effectiveness and synergy, eliminating the need for other pumps.

In Korea, it maximizes medical insurance benefits. By minimizing infusion volume, it improves patient physiological conditions while reducing healthcare provider workload, contributing to operational efficiency.

As previously explained, the development of the 5000cc/hr cartridge makes it fancy, compact, and multifunctional. Beyond enabling Anytime prescriptions and simultaneous compounding, the ACPi Pro will become the world's only equipment capable of real-time implementation of functions like rapid compounding of anticancer (injection) agents, TPN, and PCA balloon rapid filling, along with rapid IV fluid dispensing—a capability previously impossible with existing technology. As a multifunctional device, its dispensing capacity is incomparable to dispensing systems in the 10 billion range. Recently developed using syringe principles, the ACPi Pro will be unmatched by any other equipment. It can be customized for BSC use based on dispensing, filling, and infusion volumes, meeting user needs for sterile environments. With its price competitiveness, it is poised to become a blockbuster in the global market.

We aim to create a website incorporating this content.

We extend our gratitude to the judges for their hard work in the selection process.

Thnak you.